Alkyl hydroperoxide reductase: A candidate Helicobacter pylori vaccine

Vaccine

Volumn 30, Issue 26, 2012, Pages 3876-3884

  O'Riordan, Avril A ^a   Morales, Veronica Athie ^a   Mulligan, Linda ^b   Faheem, Nazia ^c   Windle, Henry J ^a   Kelleher, Dermot P ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Alkyl hydroperoxide reductase; Helicobacter pylori; Mannose; Mucosal; Pichia pastoris; Systemic; Vaccination; Vaccine

Indexed keywords

ALKYL HYDROPEROXIDE REDUCTASE; ALUMINUM POTASSIUM SULFATE; CHOLERA TOXIN; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN G; MANNOSE; MANNOSYLATED ALKYL HYDROPEROXIDE REDUCTASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; HELICOBACTER INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GLYCOPROTEINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; PEROXIREDOXINS; PICHIA; RECOMBINANT PROTEINS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84861183574     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.002     Document Type: Article

References (85)

1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1(8390):1311-1315.
2. NIH. Consensus Conference Helicobacter pylori in peptic ulcer disease. The Journal of the American Medical Association 1994, 272:65-69.
3. Eurogast. Study Group An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993, 341:1359-1362.
4. Xia H., Windle H., Marshall D., Smyth C., Keane C., O'Morain C. Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting. Gut 1995, 37:30-34.
5. Gisbert J.P. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. American Journal of Gastroenterology 2005, 100(9):2083-2099.
6. Alarcon T., Domingo D., Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. International Journal of Antimicrobial Agents 1999, 12(1):19-26.
7. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59(8):1143-1153.
8. Koletzko S., Richy F., Bontems P., Crone J., Kalach N., Monteiro M.L., et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006, 55(12):1711-1716.
9. WHO in IARC monographs on the carcinogenic risks to humans. 1994; 61:177-241.
10. Wilson K.T., Crabtree J.E. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007, 133(1):288-308.
11. Fock K.M., Ang T.L. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. Journal of Gastroenterology and Hepatology 2010, 25(3):479-486.
12. Rupnow M.F., Shachter R.D., Owens D.K., Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 2001, 20(5-6):879-885.
13. Covacci A., Telford J.L., Giudice G.D., Parsonnet J., Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 1999, 284(5418):1328-1333.
14. Perry S., de Jong B.C., Solnick J.V., de la Luz Sanchez M., Yang S., Lin P.L., et al. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS ONE 2010, 5(1):e8804.
15. Windle H.J., Kelleher D., Crabtree J.E. Childhood Helicobacter pylori infection and growth impairment in developing countries: a vicious cycle?. Pediatrics 2007, 119(3):754-759.
16. Garhart C.A., Redline R.W., Nedrud J.G., Czinn S.J. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infection and Immunity 2002, 70(7):3529-3538.
17. Kleanthous H., Myers G.A., Georgakopoulos K.M., Tibbitts T.J., Ingrassia J.W., Gray H.L., et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infection and Immunity 1998, 66(6):2879-2886.
18. Sutton P., Wilson J., Lee A. Further development of the Helicobacter pylori mouse vaccination model. Vaccine 2000, 18(24):2677-2685.
19. Del Giudice G., Covacci A., Telford J.L., Montecucco C., Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annual Review of Immunology 2001, 19:523-563.
20. Michetti P., Kreiss C., Kotloff K.L., Porta N., Blanco J.L., Bachmann D., et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999, 116(4):804-812.
21. Ermak T.H., Giannasca P.J., Nichols R., Myers G.A., Nedrud J., Weltzin R., et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. Journal of Experimental Medicine 1998, 188(12):2277-2288.
22. Radcliff F.J., Hazell S.L., Kolesnikow T., Doidge C., Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infection and Immunity 1997, 65(11):4668-4674.
23. Satin B., Del Giudice G., Della Bianca V., Dusi S., Laudanna C., Tonello F., et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. Journal of Experimental Medicine 2000, 191(9):1467-1476.
24. Ferrero R.L., Thiberge J.M., Kansau I., Wuscher N., Huerre M., Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(14):6499-6503.
25. Xue J., Bai Y., Chen Y., Wang J.D., Zhang Z.S., Zhang Y.L., et al. Expression of Helicobacter pylori AlpA protein and its immunogenicity. World Journal of Gastroenterology 2005, 11(15):2260-2263.
26. Bai Y., Zhang Y.L., Chen Y., Jin J.F., Zhang Z.S., Zhou D.Y. Cloning and expression and immunogenicity of Helicobacter pylori BabA2 gene. World Journal of Gastroenterology 2004, 10(17):2560-2562.
27. Rossi G., Ruggiero P., Peppoloni S., Pancotto L., Fortuna D., Lauretti L., et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infection and Immunity 2004, 72(6):3252-3259.
28. Every A.L., Stent A., Moloney M.B., Ng G.Z., Skene C.D., Edwards S.J., et al. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine 2011, 29(7):1514-1518.
29. Flach C.-F., Svensson N., Blomquist M., Ekman A., Raghavan S., Holmgren J. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 2011, 29(6):1235-1241.
30. Corthésy-Theulaz I., Porta N., Glauser M., Saraga E., Vaney A., Haas R., et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995, 109:115-121.
31. Doidge C., Crust I., Lee A., Buck F., Hazell S., Manne U. Therapeutic immunisation against Helicobacter infection. Lancet 1994, 343(8902):914-915.
32. Sutton P., Wilson J., Kosaka T., Wolowczuk I., Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunology and Cell Biology 2000, 78(1):28-30.
33. Eisenberg J.C., Czinn S.J., Garhart C.A., Redline R.W., Bartholomae W.C., Gottwein J.M., et al. Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infection and Immunity 2003, 71(4):1820-1827.
34. Gottwein J.M., Blanchard T.G., Targoni O.S., Eisenberg J.C., Zagorski B.M., Redline R.W., et al. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. Journal of Infectious Diseases 2001, 184(3):308-314.
35. Czinn S.J., Cai A., Nedrud J.G. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993, 11(6):637-642.
36. Marchetti M., Arico B., Burroni D., Figura N., Rappuoli R., Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995, 267(5204):1655-1658.
37. Weltzin R., Kleanthous H., Guirakhoo F., Monath T.P., Lee C.K. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 1997, 15(4):370-376.
38. Malfertheiner P., Schultze V., Rosenkranz B., Kaufmann S.H.E., Ulrichs T., Novicki D., et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008, 135(3):787-795.
39. Moss S.F., Moise L., Lee D.S., Kim W., Zhang S., Lee J., et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011, 29(11):2085-2091.
40. Baker L.M.S., Raudonikiene A., Hoffman P.S., Poole L.B. Essential thioredoxin-dependent peroxiredoxin system from Helicobacter pylori: genetic and kinetic characterization. Journal of Bacteriology 2001, 183(6):1961-1973.
41. Yan J., Kumagai T., Ohnishi M., Ueno I., Ota H. Immune response to a 26-kDa protein, alkyl hydroperoxide reductase, in Helicobacter pylori-infected Mongolian gerbil model. Helicobacter 2001, 6(4):274-282.
42. Lundström A.M., Sundaeus V., Bölin I. The 26-kilodalton, AhpC homologue, of Helicobacter pylori is also produced by other Helicobacter species. Helicobacter 2001, 6(1):44-54.
43. Wang G., Hong Y., Johnson M.K., Maier R.J. Lipid peroxidation as a source of oxidative damage in Helicobacter pylori: protective roles of peroxiredoxins. Biochimica et Biophysica Acta 2006, 1760(11):1596-1603.
44. Olczak A.A., Olson J.W., Maier R.J. Oxidative-stress resistance mutants of Helicobacter pylori. Journal of Bacteriology 2002, 184(12):3186-3193.
45. Olczak A.A., Seyler R.W., Olson J.W., Maier R.J. Association of Helicobacter pylori antioxidant activities with host colonization proficiency. Infection and Immunity 2003, 71(1):580-583.
46. Chuang M.-H., Wu M.-S., Lo W.-L., Lin J.-T., Wong C.-H., Chiou S.-H. The antioxidant protein alkylhydroperoxide reductase of Helicobacter pylori switches from a peroxide reductase to a molecular chaperone function. Proceedings of the National Academy of Sciences 2006, 103(8):2552-2557.
47. Huang C.-H., Chuang M.-H., Lo W.-L., Wu M.-S., Wu Y.-H., Wu D.-C., et al. Alkylhydroperoxide reductase of Helicobacter pylori as a biomarker for gastric patients with different pathological manifestations. Biochimie 2011, 93(7):1115-1123.
48. Papinutto E., Windle H.J., Cendron L., Battistutta R., Kelleher D., Zanotti G. Crystal structure of alkyl hydroperoxide-reductase (AhpC) from Helicobacter pylori. Biochimica et Biophysica Acta 2005, 1753(2):240-246.
49. Tan M.C., Mommaas A., Drijfhout J., Jordens R., Onderwater J., Verwoerd D., et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. European Journal of Immunology 1997, 27(9):2426-2435.
50. Lam J.S., Huang H., Levitz S.M. Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells. PLoS ONE 2007, 2(10):e1009.
51. Sheng K.-C., Kalkanidis M., Pouniotis D.S., Esparon S., Tang C.K., Apostolopoulos V., et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. European Journal of Immunology 2008, 38(2):424-436.
52. Keler T., Ramakrishna V., Fanger M.W. Mannose receptor-targeted vaccines. Expert Opinion on Biological Therapy 2004, 4(12):1953-1962.
53. Lee A., O'Rourke J., De Ungria M.C., Robertson B., Daskalopoulos G., Dixon M.F. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997, 112(4):1386-1397.
54. Kim J.S., Chang J.H., Chung S.I., Yum J.S. Importance of the host genetic background on immune responses to Helicobacter pylori infection and therapeutic vaccine efficacy. FEMS Immunology and Medical Microbiology 2001, 31(1):41-46.
55. Raghavan S., Fredriksson M., Svennerholm A.M., Holmgren J., Suri-Payer E. Absence of CD4+ CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clinical and Experimental Immunology 2003, 132(3):393-400.
56. Sutton P., Danon S.J., Walker M., Thompson L.J., Wilson J., Kosaka T., et al. Post-immunisation gastritis and Helicobacter infection in the mouse: a long term study. Gut 2001, 49(4):467-473.
57. Court M., Robinson P.A., Dixon M.F., Crabtree J.E. Gastric Helicobacter species infection in murine and gerbil models: comparative analysis of effects of H. pylori and H. felis on gastric epithelial cell proliferation. Journal of Infectious Diseases 2002, 186(9):1348-1352.
58. Diehl K.H., Hull R., Morton D., Pfister R., Rabemampianina Y., Smith D., et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. Journal of Applied Toxicology 2001, 21(1):15-23.
59. Xia H.X., English L., Keane C.T., O'Morain C.A. Enhanced cultivation of Helicobacter pylori in liquid media. Journal of Clinical Pathology 1993, 46(8):750-753.
60. Ferrero R.L., Thiberge J.M., Labigne A. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterology 1997, 113(1):185-194.
61. Wu C., Shi Y., Guo H., Zou W.-Y., Guo G., Xie Q.-H., et al. Protection against Helicobacter pylori infection in Mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine. Helicobacter 2008, 13(3):191-199.
62. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. American Journal of Surgical Pathology 1996, 20(10):1161-1181.
63. Enroth H., Berglund H., Bergstrom M., Kraaz W., Tracz P., Gustafsson S., et al. 13C-urea breath test results in pigs challenged with Helicobacter pylori or other urease producing bacteria. FEMS Immunology and Medical Microbiology 1999, 23(3):253-257.
64. Blanchard T.G., Eisenberg J.C., Matsumoto Y. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 2004, 22(7):888-897.
65. Lam J.S., Mansour M.K., Specht C.A., Levitz S.M. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. Journal of Immunology 2005, 175(11):7496-7503.
66. Luong M., Lam J.S., Chen J., Levitz S.M. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 2007, 25(22):4340-4344.
67. Blanchard T.G., Czinn S.J., Redline R.W., Sigmund N., Harriman G., Nedrud J.G. Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice. Cellular Immunology 1999, 191(1):74-80.
68. Daly R., Hearn M.T.W. Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. Journal of Molecular Recognition 2005, 18(2):119-138.
69. Pratap J., Rajamohan G., Dikshit K.L. Characteristics of glycosylated streptokinase secreted from Pichia pastoris: enhanced resistance of SK to proteolysis by glycosylation. Applied Microbiology and Biotechnology 2000, 53(4):469-475.
70. Mohammadi M., Redline R., Nedrud J., Czinn S. Role of the host in pathogenesis of Helicobacter-associated gastritis: H. felis infection of inbred and congenic mouse strains. Infection and Immunity 1996, 64(1):238-245.
71. Akhiani A.A., Pappo J., Kabok Z., Schon K., Gao W., Franzen L.E., et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. Journal of Immunology 2002, 169(12):6977-6984.
72. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. Journal of Immunology 1999, 163(12):6448-6454.
73. Amedei A., Cappon A., Codolo G., Cabrelle A., Polenghi A., Benagiano M., et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. Journal of Clinical Investigation 2006, 116(4):1092-1101.
74. D'Elios M.M., Amedei A., Cappon A., Del Prete G., de Bernard M. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunology and Medical Microbiology 2007, 50(2):157-164.
75. Velin D., Favre L., Bernasconi E., Bachmann D., Pythoud C., Saiji E., et al. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 2009, 136(7):2237-2246.
76. DeLyria E.S., Redline R.W., Blanchard T.G. Vaccination of mice against H. pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 2009, 136(1):247-256.
77. Flach C-F., Ã-stberg A.K., Nilsson A-T., Malefyt R.D.W., Raghavan S. Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase. Infection and Immunity 2011, 79(2):879-886.
78. DeLyria E.S., Nedrud J.G., Ernst P.B., Alam M.S., Redline R.W., Ding H., et al. Vaccine-induced immunity against Helicobacter pylori in the absence of IL-17A. Helicobacter 2011, 16(3):169-178.
79. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annual Review of Immunology 2009, 27(1):485-517.
80. Becher D., Deutscher M.E., Simpfendorfer K.R., Wijburg O.L., Pederson J.S., Lew A.M., et al. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. European Journal of Immunology 2010, 40(10):2778-2790.
81. Minoura T., Kato S., Otsu S., Fujioka T., Iinuma K., Nishizono A. Childhood Helicobacter pylori infection in a murine model: maternal transmission and eradication by systemic immunization using bacterial antigen-aluminium hydroxide. Clinical and Experimental Immunology 2003, 134(1):32-37.
82. Guy B., Hessler C., Fourage S., Haensler J., Vialon-Lafay E., Rokbi B., et al. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 1998, 16(8):850-856.
83. Ruggiero P., Peppoloni S., Rappuoli R., Del Giudice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man?. Microbes and Infection 2003, 5(8):749-756.
84. Krieg A.M. Toll-free vaccines?. Nature Biotechnology 2007, 25(3):303-305.
85. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314(5807):1936-1938.